Drugs /

ly2874455

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally bioavailable pan-inhibitor of fibroblast growth factor receptor (FGFR) family proteins, with potential antineoplastic activity. Upon oral administration, FGFR inhibitor LY2874455 binds to and inhibits FGFR subtypes 1 (FGFR1), 2 (FGFR2), 3 (FGFR3) and 4 (FGFR4), which results in the inhibition of FGFR-mediated signal transduction pathways. This inhibits both tumor angiogenesis and proliferation of FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, cell survival and angiogenesis.

Clinical Trials

View Clinical Trials for ly2874455

Ly2874455 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating ly2874455, 1 is phase 1 (0 open).

Acute myeloid leukemia and secondary acute myeloid leukemia are the most common diseases being investigated in ly2874455 clinical trials [2].

Drug Details

Synonyms [2]:
pan-fgfr inhibitor ly2874455
Drug Categories [2]:
FGFR1/2/3 inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
FGFR1, FGFR2, FGFR3, FGFR4

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.